A method is provided for removing red blood cells from a suspension comprising red blood cells, white blood cells, platelets and plasma using a spinning membrane separator. The method comprises: a) flowing whole blood into the gap of the spinning membrane separator; b) collecting red blood cells and white blood cells in the gap and passing plasma and platelets through the membrane; c) introducing a first quantity of lysing buffer into the gap; d) incubating the red blood cells, white blood cells and lysing buffer in the gap for a period of time to cause a lysis reaction with the red blood cells; e) introducing a second quantity of lysing buffer into the gap to displace the first quantity of lysing buffer and a first quantity of red blood cell debris out of the gap; f) introducing a first quantity of wash buffer into the gap to quench the lysis reaction and displace the second quantity of lysing buffer and a second quantity of red blood cell debris out of the gap; and g) introducing a second quantity of wash buffer into the gap to flow washed white blood cells out of the housing.

A filter and a device including the filter may include a filter and a plurality of pores arranged two-dimensionally on the filter. The plurality of pores may include a plurality of first pores having a longer structure in a certain direction and a plurality of second pores having a longer structure in a direction different from that of the first pore. The first and second pores may have a two-dimensional arrangement in order to suppress or prevent the occurrence of cracks in the filter due to stress.

A filter and a device including the filter may include a filter and a plurality of pores arranged two-dimensionally on the filter. The plurality of pores may include a plurality of first pores having a longer structure in a certain direction and a plurality of second pores having a longer structure in a direction different from that of the first pore. The first and second pores may have a two-dimensional arrangement in order to suppress or prevent the occurrence of cracks in the filter due to stress.

A portable and wearable renal therapy system is provided. The system comprises: a purification device configured to remove toxins from process fluid and deliver a therapeutic substance to the process fluid; and a drug delivery device coupled to the purification device. The drug delivery device comprises: a reservoir for a fluid comprising a therapeutic substance; and a fluid connection coupling the drug delivery device with the purification device, the fluid connection configured for fluidly communicating the reservoir with the process fluid.

The present disclosure relates to a calculation device for determining an interdialytic sodium intake of a patient and/or for determining a non-osmotically triggered interdialytic liquid intake, including a storage device and/or an input device configured for storing or for entering parameter values of the patient; a computing device, configured for calculating the interdialytic sodium intake of the patient and/or for calculating his non-osmotically triggered interdialytic liquid intake; and an output device for outputting a signal for controlling or closed-loop controlling a communication device and/or a medical blood treatment apparatus.

A method and a device for activating a function of a device, preferably of a medical device. The method includes the steps of: detecting an actual state of the device using a camera, preferably an AR device, which is preferably AR glasses; comparing the actual state of the device with a desired state of the device using a CPU connected to the camera; transmitting, on the basis of the comparison, a command for starting the function of the device or a function test, preferably a function test, from the CPU to the device; and activating the function or the function test of the device on the basis of this command.

The invention relates generally to methods of treating or reducing the risk of Cytokine Release Syndrome (CRS), treating or reducing the risk of Tumor Lysis Syndrome (TLS), or increasing drug exposure in a subject undergoing CAR T-cell therapy or chemotherapy. The methods comprise contacting blood from the subject with an extracorporeal membrane having a plurality of pores having an average pore size of at least 60 kDa to permit inflammatory cytokines, other inflammatory molecules, or metabolites to pass through the pores and out of the blood that is returned back to the subject.

The invention relates generally to methods of treating or reducing the risk of Cytokine Release Syndrome (CRS), treating or reducing the risk of Tumor Lysis Syndrome (TLS), or increasing drug exposure in a subject undergoing CAR T-cell therapy or chemotherapy. The methods comprise contacting blood from the subject with an extracorporeal membrane having a plurality of pores having an average pore size of at least 60 kDa to permit inflammatory cytokines, other inflammatory molecules, or metabolites to pass through the pores and out of the blood that is returned back to the subject.

A method of removing harmful substances in blood according to an embodiment of the present disclosure is performed by a fluidic device including an inlet into which isolated blood is injected and at least one blood-clot generating and fixing unit, and the method includes injecting isolated blood into the inlet and removing harmful substances in blood by generating blood clots in the at least one blood-clot generating and fixing unit from the injected blood and fixing the blood clots.

A method of removing harmful substances in blood according to an embodiment of the present disclosure is performed by a fluidic device including an inlet into which isolated blood is injected and at least one blood-clot generating and fixing unit, and the method includes injecting isolated blood into the inlet and removing harmful substances in blood by generating blood clots in the at least one blood-clot generating and fixing unit from the injected blood and fixing the blood clots.